New Evaluation Report - Fulvestrant

5th Jan 2018

The new evaluation report on the use of fulvestrant in the treatment of breast cancer in postmenopausal women not previously treated with endocrine therapy is now online. This review aims to give objective information and guidance on efficacy, adverse effects, place in treatment and arrangements for prescribing to commissioners of health services, prescribers and others.

Please note that these documents are restricted to stakeholders only for a period of 3 months following publication.